GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

It is important for vulnerable people and the elderly to stay up to date on vaccinations such as influenza (to protect ...

With acute respiratory infections or lung-related illnesses rising in India, experts emphasise the need for increased adult ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Voluntary vaccination among adults can significantly reduce the incidence of lung infections, leading to fewer hospital ...

However, the current rate of adult vaccination in India is minuscule due to which millions of individuals remain vulnerable ...

Shingles is “one of the worst pains in medicine.” A vaccine is highly effective at preventing it, but many people don’t get ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Voluntary vaccination among adults can significantly reduce the incidence of lung infections, leading to fewer hospital ...

PHILADELPHIA, PA, USA I September 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

More Australians will be able to get a free vaccine for the painful condition shingles. Aussies ages 18 to 64 who are classed ...